By targeting multiple pathways involved in fibrosis—such as TGF-β signaling, fibroblast proliferation, and collagen deposition—these agents could offer more effective, multifaceted approaches to slowing or halting peritoneal fibrosis progression. Here, TGFB1 is linked to Peritoneal Fibrosis.